Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87282 trials found · Page 102 of 4365
-
Radiation 'Spark' aims to boost immune attack on lung cancer
Disease control OngoingOverall survival (OS) of patients with advanced (stage IIIB/IV) non-small-cell lung cancer (NSCLC) remains short after the first line of treatment with a median OS of 12.2 months in non squamous NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death 1/ligan…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Apr 16, 2026 12:47 UTC
-
Drug boosts radiation power in fight against advanced cervical cancer
Disease control CompletedThe primary aim of the trial is to study the impact of nelfinavir on 3 year disease free survival in patients with advanced carcinoma of cervix receiving standard chemoradiation (Cisplatin and Radiotherapy). There will be two study groups. One group will receive standard treatme…
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Doctors test surgery on unborn babies to prevent lifelong kidney damage
Disease control Recruiting nowThe purpose of the study is to study the outcomes of maternal and fetal patients who are undergoing fetal intervention for severe isolated lower urinary tract obstruction (LUTO).
Phase: NA • Sponsor: Rodrigo Ruano • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC
-
One-Two punch for lung cancer: can zapping tumors boost immune drugs?
Disease control OngoingThis phase III trial studies how well nivolumab and ipilimumab works with or without local consolidation therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune s…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New cell therapy tested for deadly Post-Transplant cancer
Disease control Recruiting nowThe purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after …
Phase: PHASE3 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
Major trial tests drug to stop aggressive skin Cancer's return
Disease control OngoingThis randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's imm…
Phase: PHASE3 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 13, 2026 20:21 UTC
-
New immunotherapy challenges standard treatment for advanced liver cancer
Disease control CompletedThis Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not be surgically removed. Before enrolling Japanese pa…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New drug duo aims to stall advanced prostate cancer
Disease control OngoingThis study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
New gene therapy trial offers hope for Tough-to-Treat brain cancer
Disease control Recruiting nowStudy to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in recurrent glioblastoma multiforme.
Phase: PHASE1, PHASE2 • Sponsor: David Baskin MD • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Gene therapy trial offers hope for boys with devastating muscle disease
Disease control OngoingThis is a controlled, open-label, single-ascending dose study to evaluate the safety and tolerability of SGT-001 in adolescents and children with Duchenne muscular dystrophy (DMD). Participants will receive a single intravenous (IV) infusion of SGT-001 and will be followed for ap…
Phase: PHASE1, PHASE2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Scientists re-engineer Patient's own cells to fight advanced lymphoma
Disease control OngoingThe purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back (relapsed) or did not respond to previous treatment …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:08 UTC
-
New combo attack on Tough-to-Treat blood cancer
Disease control Recruiting nowThis phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 08, 2026 12:02 UTC
-
One shot may be enough: huge study tests Single-Dose HPV vaccine
⭐️ VACCINE ⭐️ OngoingThis phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these ty…
Phase: PHASE4 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 24, 2026 16:07 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or…
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Major trial tests new weapon against aggressive blood cancer
Disease control OngoingThis Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
Early drug treatment shows promise in stopping 'Pre-Cancer' blood disease from worsening
Prevention OngoingThe primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Prevention
Last updated Apr 13, 2026 20:22 UTC
-
Game-Changing shot could replace daily HIV prevention pill for women
Prevention OngoingThis study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Prevention
Last updated Apr 13, 2026 20:19 UTC
-
First human test of 'Bionic Eye' chip for Age-Related blindness
Symptom relief CompletedIn this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light perception using the implant.
Phase: NA • Sponsor: Science Corporation • Aim: Symptom relief
Last updated Apr 22, 2026 15:58 UTC
-
Major trial tests Immune-Boosting drug to stop aggressive bladder cancer from coming back
Disease control OngoingThis phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread into the deep muscle of the bladder wall (muscle-invasive) or urothelial cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanc…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New drug trial aims to outperform standard chemo for common blood cancers
Disease control OngoingTo compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 15, 2026 16:14 UTC